aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
0.1700
-0.0023 (-1.33%)
At close: Oct 22, 2026, 4:00 PM EDT
0.1800
+0.0100 (5.88%)
After-hours: Oct 22, 2026, 5:34 PM EDT
aTyr Pharma Employees
As of December 31, 2025, aTyr Pharma had 60 total employees, including 58 full-time and 2 part-time employees. The number of employees increased by 1 or 1.69% compared to the previous year. That makes aTyr Pharma the 34,128th largest employer in the world and 4,521st in the United States.
Employees
60
Change (1Y)
1
Growth (1Y)
1.69%
Revenue / Employee
$3,167
Profits / Employee
-$1,013,450
Market Cap
16.67M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 60 | 1 | 1.69% | 58 | 2 |
| Dec 31, 2024 | 59 | 0 | - | 56 | 3 |
| Dec 31, 2023 | 59 | -11 | -15.71% | 56 | 3 |
| Dec 31, 2022 | 70 | 17 | 32.08% | 65 | 5 |
| Dec 31, 2021 | 53 | 10 | 23.26% | 49 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 138 |
| Fractyl Health | 100 |
| Jasper Therapeutics | 22 |
| BioCardia | 21 |
| SeaStar Medical Holding | 18 |
| Psyence Biomedical | 12 |
| NewcelX | 12 |
| Cocrystal Pharma | 10 |
ATYR News
- 3 days ago - aTyr Pharma, Albert Einstein College of Medicine enter ATYR2810 pact - TheFly
- 3 days ago - aTyr Pharma Announces Research Collaboration with Montefiore Einstein - GlobeNewsWire
- 9 days ago - aTyr Pharma publishes ATYR0101 data in Journal of Biological Chemistry - TheFly
- 9 days ago - aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry - GlobeNewsWire
- 10 days ago - Ethos to Announce Third Quarter 2026 Financial Results on November 2, 2026 - GlobeNewsWire
- 23 days ago - Two stock picks from a money manager who expects small caps to roar in 2027 - Market Watch
- 4 weeks ago - Why is aTyr Pharma Stock (ATYR) Down 7% Today? - TipRanks
- 4 weeks ago - aTyr Pharma announces alignment with FDA on Phase 3 study of efzofitimod - TheFly